News | January 06, 2022
ENTOD Pharmaceuticals set to launch Molentod
It is the generic version of molnupiravir
It is the generic version of molnupiravir
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Partnering to build biosynthesis processes and a pharmaceutical production platform
A toll-free helpline to be set up to help doctors and patients
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
It will be marketed under the brand name Molunamax
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Subscribe To Our Newsletter & Stay Updated
